NMDA pathology and treatment of schizophrenia

Current Pharmaceutical Design

Volumn 20, Issue 32, 2014, Pages 5118-5126

  Chang, Huey Jen ^a,b   Lane, Hsien Yuan ^a,c   Tsai, Guochuan E ^d  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^c CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

Cognitive function; Negative symptoms; NMDA receptor hypofunction; NMDA enhancing agents; Schizophrenia

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; CYCLOSERINE; DEXTRO ALANINE; DEXTRO AMINO ACID OXIDASE; DEXTRO SERINE; GLUTAMIC ACID; GLYCINE; GLYCINE TRANSPORTER; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; N METHYL DEXTRO ASPARTIC ACID RECEPTOR STIMULATING AGENT; NEUROLEPTIC AGENT; SARCOSINE; SEROTONIN UPTAKE INHIBITOR;

ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); DRUG EFFECT; DRUG INDUSTRY; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC MODEL; HUMAN; HYPOTHESIS; NEUROTRANSMISSION; PHARMACEUTICAL CARE; PRIORITY JOURNAL; SCHIZOPHRENIA; ANIMAL; DRUG DESIGN; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOPHYSIOLOGY;

ANIMALS; ANTIPSYCHOTIC AGENTS; DRUG DESIGN; GLUTAMIC ACID; HUMANS; MOLECULAR TARGETED THERAPY; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA;

EID: 84904733019     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612819666140110121908     Document Type: Article

References (147)

1. Tsuang MT, Stone WS, Faraone SV. Towards the prevention of schizophrenia. Biol Psychiatry 2000; 48: 349-56.
2. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 1996; 153: 321-30.
3. Abi-Saab WM, D'Souza DC, Moghaddam B, Krystal JH. The NMDA antagonist model for schizophrenia: promise and pitfalls. Pharmacopsychiatry 1998; 31 Suppl 2: 104-9.
4. Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 1991; 148: 1301-8.
5. Luby ED, Cohen BD, Rosenbaum G, Gottlieb JS, Kelly R. Study of a new schizophrenic-like drug: Sernyl. Archives of Neurological Psychiatry 1959; 81: 363-9.
6. Kudoh A, Takahira Y, Katagai H, Takazawa T. Small-dose ketamine improves the postoperative state of depressed patients. Anesth Analg 2002; 95: 114-8.
7. Papouin T, Ladépêche L, Ruel J, et al. Synaptic and Extrasynaptic NMDA Receptors Are Gated by Different Endogenous Coagonists. Cell 2012; 150: 633-46.
8. Coyle JT, Puttfarcken P. Oxidative stress, glutamate and neurodegenerative disorders. Science 1993; 262: 689-95.
9. Carlsson A, Lindqvist M. Effect Of Chlorpromazine Or Haloperidol On Formation Of 3-Methoxytyramine And Normetanephrine In Mouse Brain. Acta Pharmacol Toxicol (Copenh) 1963; 20: 140-4.
10. Thaker GK, Carpenter WT Jr. Advances in schizophrenia. Nat Med 2001; 7: 667-71.
11. Marek GJ, Behl B, Bespalov AY, Gross G, Lee Y, Schoemaker H. Glutamatergic (N-Methyl-D-aspartate Receptor) Hypofrontality in Schizophrenia: Too Little Juice or a Miswired Brain? Mol Pharmacol 2010; 77: 317-26.
12. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Secondgeneration versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009; 373: 31-41.
13. Newcomer JW, Haupt DW, Fucetola R, et al. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry 2002; 59: 337-45.
14. Carlsson A, Waters N, Waters S, Carlsson ML. Network interactions in schizophrenia-therapeutic implications. Brain Research Reviews 2000; 31: 342-9.
15. Carlsson A, Hansson LO, Waters N, Carlsson ML. Neurotransmitter aberrations in schizophrenia: new perspectives and therapeutic implications. Life Sci, 1997; 61: 75-94.
16. Li T, Yang L, Wiese C, et al. No association between alleles or genotypes at the dopamine transporter gene and schizophrenia. Psychiatry Res 1994; 52: 17-23.
17. Martinez D, Gelernter J, Ali-Dargham A, et al. The variable number of tandem repeats polymorphism of the dopamine transporter gene is not associated with significant change in dopamine transporter phenotype in humans. Neuropsychopharmacology 2001; 24: 553-60.
18. Moises HW, Gelernter J, Giuffra LA, et al. No linkage between D2 dopamine receptor gene region and schizophrenia. Arch Gen Psychiatry 1991; 48: 643-7.
19. Su Y, Burke J, O’Neill FA, et al. Exclusion of linkage between schizophrenia and D2 dopamine receptor gene region of chromosome 11 q in 112 Irish multiplex families. Arch Gen Psychiatry 1993; 50: 205-11.
20. Ohara K, Nagai M, Tani K, Tsukamoto T, Ohara K. Schizophrenia and the serotonin 2A receptor promoter polymorphism. Psychiatry Res 1999; 85: 221-4.
21. Kim JS, Kornhuber HH, Holzmüller B, Schmid-Burgk W, Mergner T, Krzepinski G. Reduction of cerebrospinal fluid glutamic acid in Huntington's chorea and in schizophrenic patients. Arch Psychiatr Nervenkr 1980; 228: 7-10.
22. Nishikawa T, Takashima M, Toru M. Increased [3H]kainic acid binding in the prefrontal cortex in schizophrenia. Neurosci Lett 1983; 40: 245-50.
23. Deakin JFW, Slater P, Simpson MDC, et al. Frontal cortical and left temporal glutamatergic dysfunction in schizophrenia. J Neurochem 1989; 52: 1781-6.
24. Mechri A, Saoud M, Khiari G, d'Amato T, Dalery J, Gaha L. Glutaminergic hypothesis of schizophrenia: clinical research studies with ketamine. Encephale 2001; 27: 53-9.
25. Do KQ, Lauer CJ, Schreiber W, et al. gamma-Glutamylglutamine and taurine concentrations are decreased in the cerebrospinal fluid of drug-naive patients with schizophrenic disorders. J Neurochem 1995; 65: 2652-62.
26. Tsai G, Yang P, Chung LC, Lange N, Coyle JT. D-serine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 1998; 44: 1081-9.
27. Hashimoto K, Engberg G, Shimizu E, Nordin C, Lindstrom LH, Iyo M. Reduced d-serine to total serine ratio in the cerebrospinal fluid of drug naive schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 2005; 29: 767-9.
28. Bartha R, Williamson PC, Drost DJ, et al. Measurement of glutamate and glutamine in the medial prefrontal cortex of never-treated schizophrenic patients and healthy controls by proton magnetic resonance spectroscopy. Arch Gen Psychiatry 1997; 54: 959-65.
29. Anis NA, Berry SC, Burton NR, Lodge D. The dissociative anesthetics ketamine and phencyclidine selectively reduce excitation of central mammalian neurons by N-methyl-D-aspartate. British Journal of Pharmacology 1983; 79: 565-75.
30. Jentsch J, Roth R. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1999; 20: 201-25.
31. Tsapakis EM, Travis MJ. Glutamate and psychiatric disorders. Advances in Psychiatric Treatment 2002; 8: 189-97.
32. Starmer CF, Grant AO. Phasic ion channel blockade: A kinetic model and parameter estimation procedure. Mol Pharmacol 1985; 28: 348-56.
33. Reynolds IJ, Murphy SN, Miller RJ. 3H-labeled MK-801 binding to the excitatory amino acid receptor complex from rat brain is enhanced by glycine. Proc Natl Acad Sci USA 1987; 84: 7744-8.
34. Krystal JH, Karper LP, Seibyl JP, et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 1994; 51: 199-214.
35. Mouri A, Noda Y, Enomoto T, Nabeshima T. Phencyclidine animal models of schizophrenia: approaches from abnormality of glutamatergic neurotransmission and neurodevelopment. Neurochem Int 2007; 51: 173-84.
36. Coyle JT, Tsai G, Goff DC. Ionotropic glutamate receptors as therapeutic targets in schizophrenia. Curr Drug Targets CNS Neurol Disord 2002; 1: 183-9.
37. Lahti AC, Koffel B, LaPorte D, Tamminga CA. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 1995; 13: 9-19.
38. Moghaddam B, Adams B, Verma A, Daly D. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from the NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 1997; 17: 2921-7.
39. Holcomb HH, Lahti AC, Medoff DR, Cullen T, Tamminga CA. Effects of noncompetitive NMDA receptor blockade on anterior cingulate cerebral blood flow in volunteers with schizophrenia. Neuropsychopharmacology 2005; 30: 2275-82.
40. Tsai G. A New Class of Antipsychotic Drugs: enhancing Neurotransmission Mediated by NMDA Receptors. Psychiatric Times 2008; 25.
41. Glantz LA, Lewis DA. Decreased Dendritic Spine Density on Prefrontal Cortical Pyramidal Neurons in Schizophrenia. Arch Gen Psychiatry 2000; 57: 65-73.
42. Kwon HB, Sabatini BL. Glutamate induces de novo growth of functional spines in developing cortex. Nature 2011; 474: 100-4.
43. Tsai GE, Yang P, Chang YC, Chong MY. D-alanine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 2006; 59: 230-4.
44. Hashimoto A, Oka T. Free D-aspartate and D-serine in the mammalian brain and periphery. Prog Neurobiol 1997; 52: 325-53.
45. Balu DT, Coyle JT. Neuronal d-serine regulates dendritic architecture in the somatosensory cortex. Neuroscience Letters 2012; 517: 77-81.
46. Insel TR. Rethinking schizophrenia. Nature 2010; 468: 187-93.
47. Meltzer HY. The mechanism of action of novel antipsychotic drugs. Schiz Bull 1991; 17: 262-87.
48. Qin ZH, Zhou LW, Weiss B. D2 dopamine receptor messenger RNA is altered to a greater extent by blockade of glutamate receptors than by blockade of dopamine receptors. Neuroscience 1994; 60: 97-114.
49. Allen RM, Young SJ. Phencyclidine-induced psychosis. Am J Psychiatry 1978; 135: 1081-4.
50. Olney, JW; Labruyere, J; Wang, G; Wozniak, DF; Price, MT; Sesma MA. NMDA antagonist neurotoxicity: mechanism and prevention. Science 1991; 254: 1515-8.
51. Olney JW, Farber NB. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 1995a; 52: 998-1007.
52. Olney JW, Farber NB. NMDA antagonists as neurotherapeutic drugs, psychotogens, neurotoxins, and research tools for studying schizophrenia. Neuropsychopharmacology 1995b; 13: 335-45.
53. Moretti RJ, Hassan SZ, Goodman LI, Meltzer HY. Comparison of ketamine and thiopental in healthy volunteers: Effects on mental status, mood, and personality. Anesth Analg 1984; 63: 1087-96.
54. Cohen B, Rosenbaum G, Luby E, Gottlieb J. Comparison of phencyclidine hydrochloride (sernyl) with other drugs: simulation of schizophrenic performance with phencyclidine hydrochloride (sernyl), lysergic acid diethylamide (LSD-25), and amobarbital (Amytal) sodium, II: symbolic and sequential thinking. Arch Gen Psychiatry 1962; 6: 79-85.
55. van Berckel BN, Oranje B, van Ree JM, Verbaten MN, Kahn RS. The effects of low dose ketamine on sensory gating, neuroendocrine secretion and behavior in healthy human subjects. Psychopharmacology (Berl) 1998; 137: 271-81.
56. Newcomer JW, Haupt DW, Fucetola R, et al. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry 2002; 59: 337-45.
57. Luby ED. Phencyclidine revisited. In: Domino EF ed. PCP (Phencyclidine): Historical and current perspectives. Michigan: NPP Books. 1981, 425-30.
58. Tamminga CA. Glutamatergic aspects of schizophrenia. Br J Psychiatry 1999; Suppl 37: 12-5.
59. Nicodemus KK, Law AJ, Radulescu E, et al. Biological Validation of Increased Schizophrenia Risk With NRG1, ERBB4, and AKT1 Epistasis via Functional Neuroimaging in Healthy Controls. Arch Gen Psychiatry 2010; 67: 991-1001.
60. Shi J, Gershon ES, Liu C. Genetic associations with schizophrenia: meta-analyses of 12 candidate genes. Schizophr Res 2008; 104: 96-107.
61. Shirts BH, Nimgaonkar V. The genes for schizophrenia: finally a breakthrough? Curr Psychiatry Rep 2004; 6: 303-12.
62. Song G, Ouyang G, Bao S. The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med 2005; 9: 59-71.
63. Emamian ES, Happ D, Birnbaum MJ, Karayiorgou M, Gogos JA. Convergent evidence for impaired AKT1-GSK3B signaling in schizophrenia. Nat Genet 2004; 36: 131-7.
64. Thiselton DL, Vladimirov VI, Kuo PH, et al. AKT1 is associated with schizophrenia across multiple symptom dimensions in the Irish study of high density schizophrenia families. Biol Psychiatry 2008; 63: 449-57.
65. Abou JR, Schmael C, Cichon S, Rietschel M, Schumacher J, Nöthen MM. The G72/G30 gene locus in psychiatric disorders: a challenge to diagnostic boundaries? Schizophr Bull 2006; 32: 599-608.
66. McGuffin P, Tandon K, Corsico A. Linkage and association studies of schizophrenia. Curr Psychiatry Rep 2003; 5: 121-7.
67. Sei Y, Ren-Patterson R, Li Z, et al. Neuregulin1-induced cell migration is impaired in schizophrenia: association with neuregulin1 and catechol-o-methyltransferase gene polymorphisms. Mol Psychiatry 2007; 12: 946-57.
68. Stefansson H, Sigurdsson E, Steinthorsdottir V, et al. Neuregulin 1 and susceptibility to schizophrenia. Am J Hum Genet 2002; 71: 877-92.
69. Pitcher GM, Kalia LV, Ng D, et al. Schizophrenia susceptibility pathway neuregulin 1-ErbB4 suppresses Src upregulation of NMDA receptors. Nat Med 2011; 17: 470-8.
70. Benson MA, Newey SE, Martin-Rendon E, Hawkes R, Blake DJ. Dysbindin, a novel coiled-coil-containing protein that interacts with the dystrobrevins in muscle and brain. J Biol Chem 2001; 276: 24232-41.
71. Blake DJ, Weir A, Newey SE, Davies KE. Function and genetics of dystrophin and dystrophin-related proteins in muscle. Physiol Rev 2002; 82: 291-329.
72. Blake DJ, Hawkes R, Benson MA, Beesley PW. Different dystrophin-like complexes are expressed in neurons and glia. J Cell Biol 1999; 147: 645-57.
73. Benes FM. Emerging principles of altered neural circuitry in schizophrenia. Brain Res Rev 2000; 31: 251-69.
74. Talbot K, Eidem WL, Tinsley CL, et al. Dysbindin-1 is reduced in intrinsic, glutamatergic terminals of the hippocampal formation in schizophrenia. J Clin Invest 2004; 113: 1353-63.
75. Clelland CL, Read LL, Baraldi AN, et al. Evidence for association of Hyperprolinemia with Schizophrenia and a Measure of Clinical Outcome. Schizophr Res 2011; 131: 139-145.
76. Bender HU, Almashanu S, Steel G, et al. Functional consequences of PRODH missense mutations. Am J Hum Genet 2005; 76: 409-20.
77. Karayiorgou M, Simon TJ, Gogos JA. 22q11.2 microdeletions: linking DNA structural variation to brain dysfunction and schizophrenia. Nat Rev Neurosci 2010; 11: 402-16.
78. Schosser A, Aschauer HN. In search of susceptibility genes for schizophrenia. Wien Klin Wochenschr 2004; 116: 827-33.
79. Egan MF, Goldberg TE, Kolachana BS, et al. Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci USA 2001; 98: 6917-22.
80. Goldberg TE, Egan MF, Gscheidle T, et al. Executive subprocesses in working memory: Relationship to catechol-O-methyltransferase Val158Met genotype and schizophrenia. Arch Gen Psychiatry 2003; 60: 889-96.
81. Uezato A, Kimura-Sato J, Yamamoto N, Iijima Y, Kunugi H, Nishikawa T. Further evidence for a male-selective genetic association of synapse-associated protein 97 (SAP97) gene with schizophrenia. Behav Brain Funct 2012; 8: 2.
82. Cherlyn SY, Woon PS, Liu JJ, Ong WY, Tsai GC, Sim K. Genetic association studies of glutamate, GABA and related genes in schizophrenia and bipolar disorder: a decade of advance. Neurosci Biobehav Rev 2010; 34: 958-77.
83. Wolosker H, Blackshaw S, Snyder S. Serine racemase: A glial enzyme synthesizing D-serine to regulate glutamate-N-methyl-Daspartate neurotransmission. Proc Natl Acad Sci USA 1999a; 96: 13409-14.
84. Wolosker H, Sheth K, Takahashi M, et al. Purification of serine racemase: Biosynthesis of the neuromodulator D-serine. Proc Natl Acad Sci USA 1999b; 96: 721-5.
85. Verrall L, Burnet PWJ, Betts JF, Harrison PJ. The neurobiology of D-amino acid oxidase (DAO) and its involvement in schizophrenia. Mol Psychiatry 2010; 15: 122-37.
86. Hashimoto K, Fukushima T, Shimizu E, et al. Decreased serum levels of d-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia. Arch Gen Psychiatry 2003; 60: 572-6.
87. Yamada K, Ohnishi T, Hashimoto K, et al. Identification of multiple serine racemase (SRR) mRNA isoforms and genetic analyses of SRR and DAO in schizophrenia and d-serine levels. Biol Psychiatry 2005; 57: 1493-503.
88. Allen NC, Bagade S, McQueen MB, et al. Systematic Meta-Analyses and Field Synopsis of Genetic Association Studies in Schizophrenia: The SzGene Database Nat Genet 2008; 40: 827-34.
89. Roussos P, Giakoumaki SG, Adamaki E, Anastasios G, Nikos R, Bitsios P. The Association of Schizophrenia Risk D-Amino Acid Oxidase Polymorphisms With Sensorimotor Gating, Working Memory and Personality in Healthy Males. Neuropsychopharmacology 2011; 36: 1677-88.
90. Greenwood TA, Lazzeroni LC, Murray SS, Cadenhead KS, Calkins ME, Dobie DJ. Analysis of 94 Candidate Genes and 12 Endophenotypes for Schizophrenia from the Consortium on the Genetics of Schizophrenia. Am J Psychiatry 2011; 168: 930-46.
91. NCT00001486. A Neurobiological Investigation of Patients With Schizophrenia Spectrum Disorders and Their Siblings. Available at: http://www.clinicaltrials.gov/ct2/show/NCT00001486?term=NCT0 0001486&rank=1.
92. Tsai G, Lin PY. Strategies to enhance N-methyl-D-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis. Curr Pharm Des 2010; 16: 522-37.
93. Rosse RB, Theut SK, Banay-Schwartz M, et al. Glycine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label, pilot study. Clin Neuropharmacol 1989; 12: 416-24.
94. Javitt DC, Zylberman I, Zukin SR, Heresco-Levy U, Lindenmayer, JP. Amelioration of negative symptoms in schizophrenia by glycine. Am J Psychiatry 1994; 151: 1234-6.
95. Heresco-Levy U, Javitt DC, Ermilov M, Mordel C, Silipo G, Lichtenstein M. Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch Gen Psychiatry 1999; 56: 29-36.
96. Javitt DC, Silipo G, Cienfuegos A, et al. Adjunctive high-dose glycine in the treatment of schizophrenia. Int J Neuropsychopharmacol 2001; 4: 385-91.
97. Heresco-Levy U, Javitt DC, Ermilov M, Mordel C, Horowitz A, Kelly D. Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia. Br J Psychiatry 1996; 169: 610-7.
98. Chaves C, Marque CR, Trzesniak C, et al. Glutamate-N-methyl-Daspartate receptor modulation and minocycline for the treatment of patients with schizophrenia: an update. Braz J Med Biol Res 2009; 42: 1002-14.
99. Buchanan RW, Javitt DC, Marder SR, et al. The cognitive and negative symptoms in schizophrenia trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am J Psychiatry 2007; 164: 1593-602.
100. [100] Heresco-Levy U, Ermilov M, Lichtenberg P, Bar G, Javitt DC. High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia. Biol Psychiatry 2004; 55: 165-71.
101. [101] Bucldey P, Miller A, Olsen J, Qarver D, Miller DD, Csernansky J. When Symptoms Persist: Clozapine Augmentation Strategies. Schizophrenia Bulletin 2001; 27: 615-28.
102. [102] Kontaxakis VP, Ferentinos PP, Havaki-Kontaxaki BJ, Roukas DK. Randomized controlled augmentation trials in clozapine-resistant schizophrenic patients: a critical review. Eur Psychiatry 2005; 20: 409-15.
103. [103] Leiderman E, Zylberman I, Zukin SR, Cooper TB, Javitt DC. Preliminary investigation of high-dose oral glycine on serum levels and negative symptoms in schizophrenia: an open label trial. Biol Psychiatry 1996; 39: 213-5.
104. [104] Potkin SG, Jin Y, Bunney BG, Costa J, Gulasekaram B. Effect of clozapine and adjunctive high-dose glycine in treatment-resistant schizophrenia. Am J Psychiatry 1999; 156: 145-7.
105. [105] Evins AE, Fitzgerald SM, Wine L, Rosselli R, Goff DC. Placebocontrolled trial of glycine added to clozapine in schizophrenia. Am J Psychiatry 2000; 157: 826-8.
106. [106] Diaz P, Bhaskara S, Dursun SM, Deakin B. Double-blind, placebocontrolled, crossover trial of clozapine plus glycine in refractory schizophrenia negative results. J Clin Psychopharmacol 2005; 25: 277-8.
107. [107] Kinney GG, Sur C. Glycine Site Modulators and Glycine Transporter-1 Inhibitors as Novel Therapeutic Targets for the Treatment of Schizophrenia. Current Neuropharmacology 2005; 3: 35-43.
108. [108] Tsai GE, Yang P, Chung LC, Tsai IC, Tsai CW, Coyle JT. D-serine added to clozapine for the treatment of schizophrenia. Am J Psychiatry 1999; 156: 1822-5.
109. [109] Heresco-Levy U, Javitt DC, Ebstein R, et al. D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia. Biol Psychiatry 2005; 57: 577-85.
110. [110] Lane HY, Chang YC, Liu YC, Chiu CC, Tsai GE. Sarcosine or Dserine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study. Arch Gen Psychiatry 2005; 62: 1196-204.
111. [111] Kantrowitz JT, Malhotra AK, Cornblatt B, Silipo G, Balla A, Suckow RF, et al. High dose D-serine in the treatment of schizophrenia. Schizophr Res 2010; 121: 125-30.
112. [112] Lane HY, Lin CH, Huang YJ, Liao CH, Chang YC, Tsai GE. A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophrenia. Int J Neuropsychopharmacol 2010; 13: 451-60.
113. [113] Sawa A, Snyder SH. Schizophrenia: Neural Mechanisms for Novel Therapies. Molecular Medicine 2003; 9: 3-9.
114. [114] Monahan JB, Handelmann GE, Hood WF, Cordi AA. Dcycloserine, a positive modulator of the N-methyl-D-aspartate receptor, enhances performance of learning tasks in rats. Pharmacology, Biochemistry, and Behavior 1989; 34: 649-53.
115. [115] Priestley T, Kemp JA. Kinetic study of the interactions between the glutamate and glycine recognition sites on the N-methyl-D-aspartic acid receptor complex. Molecular Pharmacology 1994; 46: 1191-6.
116. [116] Hood WF, Compton RP, Monahan JB. D-cycloserine: a ligand for the N-methyl-D-aspartate coupled glycine receptor has partial agonist characteristics. Neuroscience Letters 1989; 98: 91-5.
117. [117] Watson GB, Bolanowski MA, Baganoff MP, Deppeler CL, Lanthorn TH. D-cycloserine acts as a partial agonist at the glycine modulatory site of the NMDA receptor expressed in Xenopus oocytes. Brain Research 1990; 510: 158-60.
118. [118] Goff DC, Tsai G, Manoach DS, Flood J, Darby DG, Coyle JT. Dcycloserine added to clozapine for patients with schizophrenia. Am J Psychiatry 1996; 153: 1628-30.
119. [119] Simeon J, Fink M, Itil TM, Ponce D. D-Cycloserine therapy of psychosis by symptom provocation. Comp Psychiatry 1970; 11: 80-8.
120. [120] Cascella NG, Macciardi F, Cavallini C, Smeraldi E. D-Cycloserine adjuvant therapy to conventional neuroleptic treatment in zchizophreania: An open-label study. J Neural Transm-Gen Sect 1994; 95: 105-11.
121. [121] van Berckel BN, Evenblij CN, van Loon BJ, et al. D-cycloserine increases positive symptoms in chronic schizophrenic patients when administered in addition to antipsychotics: a double-blind, parallel, placebo-controlled study. Neuropsychopharmacology 1999; 21: 203-10.
122. [122] Goff DC, Tsai G, Manoach DS, Coyle JT. Dose-finding trial of Dcycloserine added to neuroleptics for negative symptoms in schizophrenia. Am J Psychiatry 1995; 152: 1213-5.
123. [123] Goff DC, Tsai G, Levitt J, et al. A placebo-controlled trial of Dcycloserine added to conventional neuroleptics in patients with schizophrenia. Arch Gen Psychiatry 1999; 56: 21-7.
124. [124] Heresco-Levy U, Ermilov M, Shimoni J, Shapira B, Silipo G, Javit, DC. Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia. Am J Psychiatry 2002; 159: 480-2.
125. [125] Duncan EJ, Szilagyi S, Schwartz MP, et al. Effects of Dcycloserine on negative symptoms in schizophrenia. Schizophr Res 2004; 71: 239-48.
126. [126] Goff DC, Herz L, Posever T, et al. A six-month, placebo-controlled trial of D-cycloserine co-administered with conventional antipsychotics in schizophrenia patients. Psychopharmacology 2005; 179: 144-50.
127. [127] Heresco-Levy U, Javitt DC, Ermilov M, Silipo G, Shimoni J. Double-blind, placebo-controlled, crossover trial of D-cycloserine adjuvant therapy for treatment-resistant schizophrenia. Int J Neuropsychopharmacol 1998; 1: 131-5.
128. [128] Evins AE, Amico E, Posever TA, Toker R, Goff DC. D-cycloserine added to risperidone in patients with primary negative symptoms of schizophrenia. Schizophr Res 2002; 56: 19-23.
129. [129] Hollmann M, Heinemann S. Cloned glutamate receptors. Annu Rev Neurosci 1994; 17: 31-108.
130. [130] Depoortère R, Dargazanli G, Estenne-Bouhtou G, et al. Neurochemical, electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter-1 SSR504734, a potential new type of antipsychotic. Neuropsychopharmacology 2005; 30: 1963-85.
131. [131] Adams RH, Sato K, Shimada S, Tohyama M, Püschel AW, Betz H. Gene structure and glial expression of the glycine transporter GlyT1 in embryonic and adult rodents. J Neurosci 1995; 15: 2524-32.
132. [132] Zafra F, Aragon C, Olivares L, Danbolt NC, Gimenez C, Storm-Mathisen J. Glycine transporters are differentially ssed among CNS cells. J Neurosci 1995; 15: 3952-69.
133. [133] Berger AJ, Dieudonne S, Ascher P. Glycine uptake governs glycine site occupancy at NMDA receptors of excitatory synapses. J Neurophysiol 1998; 80: 3336-40.
134. [134] Roux MJ, Supplisson S. Neuronal and glial glycine transporters have different stoichiometries. Neuron 2000; 25: 373-83.
135. [135] Tsai G, Lane HY, Yang P, Chong MY, Lange N. Glycine transporter I inhibitor, N-methylglycine (sarcosine) added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 2004; 55: 452-6.
136. [136] Lane HY, Liu YC, Huang CL, et al. Sarcosine (N-methylglycine) treatment for acute schizophrenia: a randomized, double-blind study. Biol Psychiatry 2008; 63: 9-12.
137. [137] Lane HY, Huang CL, Wu PL, et al. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia. Biol Psychiatry 2006; 60: 645-9.
138. [138] Mothet JP, Parent AT, Wolosker H, et al. D-serine is an endogenous ligand for the glycine site of the N-methyl-d-aspartate receptor. Proc Natl Acad Sci USA 2000; 97: 4926-31.
139. [139] Liu X, He G, Wang X, et al. Association of DAO with schizophrenia in the Chinese population. Neurosci Lett 2004; 369: 228-33.
140. [140] Schumacher J, Jamra RA, Freudenberg J, et al. Examination of G72 and damino-acid oxidase as genetic risk factors for schizophrenia and bipolar affective disorder. Mol Psychiatry 2004; 9: 203-7.
141. [141] Wood LS, Pickering EH, Dechairo BM. Significant support for DAO as a schizophrenia susceptibility locus: examination of five genes putatively associated with schizophrenia. Biol Psychiatry 2007; 61: 1195-9.
142. [142] Boks MP, Rietkerk T, van de Beek MH, Sommer IE, de Koning TJ, Kahn RS. Reviewing the role of the genes G72 and DAAO in glutamate neurotransmission in schizophrenia. Eur Neuropsychopharmacol 2007; 17: 567-72.
143. [143] Sacchi S, Cappelletti P, Giovannardi S, Pollegioni L. Evidence for the interaction of d-amino acid oxidase with pLG72 in a glial cell line. Mol Cell Neurosci 2011; 48: 20-8.
144. [144] Madeira C, Freitas ME, Vargas-Lopes C, Wolosker H, Panizzutti R. “Increased brain d-amino acid oxidase (DAAO) activity in schizophrenia”. Schizophr Res 2008; 101: 76-83.
145. [145] Habl G, Zink M, Petroianu G, et al. Increased D-amino acid oxidase expression in the bilateral hippocampal CA4 of schizophrenic patients: a post-mortem study. J Neural Transm 2009; 116: 1657-65.
146. [146] Labrie V, Duffy S, Wang W, Barger SW, Baker GB, Roder JC. Genetic inactivation of D-amino acid oxidase enhances extinction and reversal learning in mice. Learn Mem 2008; 16: 28-37.
147. [147] Labrie V, Wang W, Barger SW, Baker GB, Roder JC. Genetic loss of D-amino acid oxidase activity reverses schizophrenia-like phenotypes in mice. Genes Brain Behav 2010; 9: 11-25.